Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jordan S Fridman

Showing results (1-10 of 31) with videos related to

Pageof 4
Sort By:
JAK-STAT|September 24, 2013
The interplay between inhibition of JAK2 and HSP90Jordan S Fridman, Nicholas J Sarlis
Oncogene|December 10, 2003
Control of apoptosis by p53Jordan S Fridman, Scott W Lowe
Cancer Cell|June 28, 2002
Dissecting p53 tumor suppressor functions in vivoClemens A Schmitt, Jordan S Fridman, Meng Yang, et al.
Cancer Research|October 3, 2003
Tumor promotion by Mdm2 splice variants unable to bind p53Jordan S Fridman, Eva Hernando, Michael T Hemann, et al.
Cell|May 23, 2002
A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapyClemens A Schmitt, Jordan S Fridman, Meng Yang, et al.
Expert Opinion on Investigational Drugs|July 12, 2005
ADAM proteases, ErbB pathways and cancerBin-Bing S Zhou, Jordan S Fridman, Xiangdong Liu, et al.
Nature Genetics|February 5, 2003
An epi-allelic series of p53 hypomorphs created by stable RNAi produces distinct tumor phenotypes in vivoMichael T Hemann, Jordan S Fridman, Jack T Zilfou, et al.
Nature|March 19, 2004
Survival signalling by Akt and eIF4E in oncogenesis and cancer therapyHans-Guido Wendel, Elisa De Stanchina, Jordan S Fridman, et al.
The New England Journal of Medicine|September 17, 2010
Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosisSrdan Verstovsek, Hagop Kantarjian, Ruben A Mesa, et al.
Cancer Biology & Therapy|April 22, 2006
Selective inhibition of ADAM metalloproteases blocks HER-2 extracellular domain (ECD) cleavage and potentiates the anti-tumor effects of trastuzumabXiangdong Liu, Jordan S Fridman, Qian Wang, et al.
Pageof 4

Showing results (1-10 of 31) with videos related to

Sort By:
Pageof 4
JAK-STAT|September 24, 2013
The interplay between inhibition of JAK2 and HSP90Jordan S Fridman, Nicholas J Sarlis
Oncogene|December 10, 2003
Control of apoptosis by p53Jordan S Fridman, Scott W Lowe
Cancer Cell|June 28, 2002
Dissecting p53 tumor suppressor functions in vivoClemens A Schmitt, Jordan S Fridman, Meng Yang, et al.
Cancer Research|October 3, 2003
Tumor promotion by Mdm2 splice variants unable to bind p53Jordan S Fridman, Eva Hernando, Michael T Hemann, et al.
Cell|May 23, 2002
A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapyClemens A Schmitt, Jordan S Fridman, Meng Yang, et al.
Expert Opinion on Investigational Drugs|July 12, 2005
ADAM proteases, ErbB pathways and cancerBin-Bing S Zhou, Jordan S Fridman, Xiangdong Liu, et al.
Nature Genetics|February 5, 2003
An epi-allelic series of p53 hypomorphs created by stable RNAi produces distinct tumor phenotypes in vivoMichael T Hemann, Jordan S Fridman, Jack T Zilfou, et al.
Nature|March 19, 2004
Survival signalling by Akt and eIF4E in oncogenesis and cancer therapyHans-Guido Wendel, Elisa De Stanchina, Jordan S Fridman, et al.
The New England Journal of Medicine|September 17, 2010
Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosisSrdan Verstovsek, Hagop Kantarjian, Ruben A Mesa, et al.
Cancer Biology & Therapy|April 22, 2006
Selective inhibition of ADAM metalloproteases blocks HER-2 extracellular domain (ECD) cleavage and potentiates the anti-tumor effects of trastuzumabXiangdong Liu, Jordan S Fridman, Qian Wang, et al.
Pageof 4